10 Most Profitable US Stocks to Buy

8. Johnson & Johnson (NYSE:JNJ)

Net Income (TTM): $25.12 billion

Operating Margin (TTM): 30.20%

Number of Hedge Fund holdings: 103

On January 9, Lee Hambright at Bernstein raised the price target on Johnson & Johnson (NYSE:JNJ) to $208 from $193 and kept the ‘Market Perform’ rating unchanged, according to TheFly.

The firm noted that U.S. healthcare stocks have shown improved performance over the last few months, following a low point in September 2025. With clearer visibility into macroeconomic uncertainties that have challenged healthcare stocks throughout 2025, Bernstein has a more favorable outlook for 2026.

Three days earlier, on January 6, Stifel also raised the price target on Johnson & Johnson (NYSE:JNJ) to $205 from $190, keeping a ‘Hold’ rating on the stock. This upward revision in target follows the company’s completion of its approximately $3.05 billion acquisition of Halda Therapeutics on December 29, 2025.

Stifel highlighted that the Halda acquisition is projected to be dilutive to Johnson & Johnson’s (NYSE:JNJ) adjusted earnings per share by a total of $0.20, with $0.10 of the impact in each of 2025 and 2026.

Johnson & Johnson (NYSE:JNJ) is a global healthcare company focused on innovative medicines and medical technologies. Headquartered in New Jersey, the company serves a wide clientele, including retailers, wholesalers, healthcare professionals, and hospitals.